GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Marketable Securities

Cytokinetics (FRA:KK3A) Marketable Securities : €459.07 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cytokinetics's Marketable Securities for the quarter that ended in Mar. 2024 was €459.07 Mil.

Cytokinetics's annual Marketable Securities increased from Dec. 2021 (€317.69 Mil) to Dec. 2022 (€676.84 Mil) but then declined from Dec. 2022 (€676.84 Mil) to Dec. 2023 (€460.15 Mil).


Cytokinetics Marketable Securities Historical Data

The historical data trend for Cytokinetics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Marketable Securities Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 169.81 313.24 317.69 676.84 460.15

Cytokinetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 525.23 458.81 411.86 460.15 459.07

Cytokinetics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Cytokinetics  (FRA:KK3A) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Cytokinetics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics (FRA:KK3A) Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines